script.reportAU
Women's health

Drospirenone with ethinylestradiol

Brand: Yaz, Yasmin

PBAC's latest decision on Drospirenone with ethinylestradiol: Not recommended (2024). Considered for Oral contraception. Yaz is also TGA-registered for treatment of moderate acne vulgaris and symptoms of premenstrual dysphoric disorder (PMDD) in women using oral contraception.

PBAC outcome
Not recommended
2024
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
2
first 2024
Submissions
2
2024 → 2024

Eligible population

Individuals requiring oral contraception (requested as Unrestricted benefit)

Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Other
Primary endpoint
Contraception
Comparator
PBS-listed combined oral contraceptives (levonorgestrel-based COCs)
Economic model
Not modelled
ICER note
No economic analysis was provided by the sponsor.

Why PBAC said no

Reasons cited in the latest PSD: Lack of adequate comparative effectiveness data, lack of adequate comparative safety data, no economic analysis provided

Submission history

Similar precedents

Open on full dashboard →